Patients with IDH and TERTp glioma mutations have the best prognosis whereas only IDH mutation patients and only TERTp mutation patients have the worst prognosis (Robinson & Kleinschmidt‐DeMasters, 2017). This evidence concerns the gene IDH1 and central nervous system cancer.